Vitamin D receptor/SMAD genomic circuit gates fibrotic response
The present disclosure provides compositions that include a nanoparticle and a compound that increases the biological activity of the vitamin D receptor (VDR) (e.g., a VDR agonist), and methods of using such compounds to increase retention or storage of vitamin A, vitamin D, and/or lipids by a cell, such as an epithelial or stellate cell. Such methods can be used to treat or prevent fibrosis.
1. A method for increasing or retaining vitamin A, vitamin D, and/or lipid in an epithelial or stellate cell, comprising:
contacting a therapeutically effective amount of a composition with the epithelial or stellate cell, wherein the composition comprises:
a nanoparticle comprising retinol palmitate on its surface; and
a vitamin D receptor (VDR) agonist, which is in or attached to the nanoparticle, thereby increasing or retaining vitamin A, vitamin D, and/or lipid in the epithelial or stellate cell.
2. The method of claim 1 , wherein the epithelial or stellate cell is in a subject, and wherein contacting comprises administering a therapeutically effective amount of the composition to the subject, thereby increasing or retaining vitamin A, vitamin D, and/or lipid in the epithelial or stellate cell.
3. The method of claim 1 , wherein the subject has a liver disease, kidney disease, or pancreatic disease.
4. The method of claim 3 , wherein the liver disease is one or more of alcohol liver disease, fatty liver disease, liver fibrosis/cirrhosis, biliary fibrosis/cirrhosis, liver cancer, hepatitis B virus infection, hepatitis C virus infection, sclerosing cholangitis, Budd-Chiari syndrome, jaundice, nonalcoholic steatohepatitis, hemochromatosis, or Wilson's disease.
5. The method of claim 4 , wherein the liver cancer is a hepatocellular carcinoma, cholangiocarcinoma, angiosarcoma, or hemangiosarcoma.
6. The method of claim 3 , wherein the pancreatic disease is pancreatic fibrosis or pancreatic ductal adenocarcinoma (PDA).
7. The method of claim 3 , wherein the kidney disease is fibrosis of the kidney.
8. The method of claim 1 , wherein the nanoparticle comprises a lipid nanoparticle or polymeric nanoparticle.
9. The method of claim 1 , wherein the composition further comprises a chemotherapeutic, a biologic, or combinations thereof.
10. The method of claim 9 , wherein the chemotherapeutic comprises paclitaxel.
11. The method of claim 1 , wherein the VDR agonist is vitamin D, a vitamin D precursor, a vitamin D analog, a vitamin D receptor ligand, a vitamin D receptor agonist precursor, or combinations thereof.
12. The method of claim 1 , wherein the VDR agonist is calcipotriol, 25-hydroxy-D 3 (25-OH-D 3 ) (calcidiol); vitamin D3 (cholecalciferol); vitamin D2 (ergocalciferol), 1α,25-dihydroxyvitamin D 3 (calcitriol), or combinations thereof.
13. A method for treating pancreatic fibrosis in a subject, comprising:
administering to the subject a therapeutically effective amount of a composition comprising
a nanoparticle comprising retinyl palmitate on its surface,
paclitaxel, which is in or attached to the nanoparticle, and
calcipotriol, which is in or attached to the nanoparticle,
thereby treating the pancreatic fibrosis in the subject.
14. The method of claim 13 , wherein the administering comprises orally administering a therapeutically effective amount of the composition into the subject.
15. The method of claim 13 , wherein the administering comprises intravenously, intrathecally, intramuscularly, intraperitoneally, intra-articularly, intratumorally, or subcutaneously administering a therapeutically effective amount of the composition into the subject.
16. The method of claim 13 , wherein the subject is a human subject.